Related Experiment Video

Updated: Jun 10, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma

Ming-Mo Hou1, Jia-Juan Hsieh, Nai-Jen Chang

  • 1Division of Haematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.

Clinical Drug Investigation
|July 20, 2010
PubMed

Insights

Sorafenib effectively treated metastatic Xp11 translocation renal cell carcinoma (RCC) in an 18-year-old male. This rare cancer subtype showed significant regression and improved survival with sorafenib therapy.

Area of Science:

  • Oncology
  • Medical research

Background:

  • Metastatic renal cell carcinoma (RCC) is a significant clinical challenge.
  • Sorafenib is a multikinase inhibitor approved for certain cancers.
  • Xp11 translocation carcinoma is a rare and aggressive subtype of RCC.

Observation:

  • An 18-year-old male presented with metastatic Xp11 translocation RCC.
  • The patient received treatment with sorafenib.
  • Tumor response was assessed via CT scans.

Findings:

  • Sorafenib treatment led to increased central necrosis in kidney and lymph node masses.
  • Lung and pleural masses showed significant regression.
  • The patient achieved a progression-free survival of 12 months and overall survival of 15 months.
  • Grade 3 dermatitis and anemia were the most severe adverse effects.

Implications:

  • This case demonstrates the efficacy of sorafenib in treating Xp11 translocation RCC.
  • Sorafenib represents a potential therapeutic option for this rare RCC subtype.
  • Further research into sorafenib's role in rare RCC subtypes is warranted.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...